• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Rituximab and ME/CFS in the UK - MEA update

Messages
17
When biomarkers and case definitions can't be agreed upon, how on earth can we know, for certain who, using rituxan privately or outside clinical trials, actually has what is thought of as ME/CFS/CFID/SEID? The complexity of neuroimmune and autoimmune disease is so vast and unknown, the constellation of symptoms that is now commonly associated with ME/CFS may end up being 5 or 10 or 20 distinct problems.

For almost 2 years (being sick for longer), my young adult daughter has been in the academic medical diagnostic system after an initial ME/CFS diagnosis from a recognized ME doc in the US. She has seen many specialists and subspecialists. She has had hundreds of labs, various scans, and procedures. She is now at a point where one of her subspecialists has data--and a potential measurement to see if therapy is effective-- that may warrant treatment with IV immunomodulator therapy like Rituxan.

There is no way in hell that she is going to turn that opportunity down if she gets it.

I personally think that any patient who can get it prescribed and who is educated about the risks should have the chance to take it. Compassionate use. Spending the pension or the school fund--whatever. Patients rights. Get the governments and rhe bureaucrats out of the way. People have sufferred long enough. It is a human rights violation that people have to choose between their pension and a potential treatment, but if doing nothing means you will ever have a shot at getting better, where is the choice really? Do nothing and stay sick or take a risk--a gamble--and maybe get a shot at being able to fight for those rights.

If there are millions of people with ME/CFS globally, the people on this forum are hardly a statistically significant representation of the complete disease picture. Some anecdotal reports are far from being scientifically significant without the concrete data that demonstrates effectiveness or lack of effectiveness of the therapy. Where is the lab or biopsy or other objective marker that says, "we can say conclusively that Rituxan did or did not help this patient based on the changes or lack of changes in X or Y." How is it possible to know without those markers whether sleep issues, inflammation, or digestive changes or increase in fatigue were caused by Rituxan and not perhaps, another factor? That is what is so frustrating about this disease--is half the time you can't even be sure that 5 people in the room who all supposedly have the ME diagnosis actually have the same ME--and it isn't Lyme, or paraneoplastic syndrome or some obscure autoimmune condition of a weird neurotransmitter like anti-NDMA receptor encephalitis turned out to be.

That being said, the one thing that everyone in this forum has in common is that the medical community has failed them. At this point, in my mind, anything goes. If you can get it, go for it. Rituxan, IV Ig--whatever it takes. The healing has to start somewhere.
 

alex3619

Senior Member
Messages
13,810
Location
Logan, Queensland, Australia
Very good point Bob, I think that's quite likely to be the case and it does appear that those who were non-responders in the Phase 2 trial tended to be the sickest and most long-term patients. (I'm not sure whether they've published anything to that effect, but they've mentioned it once or twice in IiME presentations as I recall).
In determining results outside of a formal study, like anecdotal reports, we need to keep in mind that there may be wildly differing protocols involved.

I personally suspect Rituximab will only have a 50% early (under two years) response rate in the final analysis. However I also suspect that after repeated treatments then more and more will respond permanently (in long term remission perhaps, but not cure), and many non-responders will respond. We really do need a marker for responders or non-responders. We really do need to know what happens to the response rate in long term patients under treatment. We do know that it sometimes takes 18 months of treatment to respond. How many of these anecdotal reports are for patients who are too sick to do that, or cannot afford it financially? How do we know how they might have responded with longer treatment?

I am hoping the phase 3 clinical trial can resolve some of these issues, or at least point to what research to do next.
 
Last edited:

alex3619

Senior Member
Messages
13,810
Location
Logan, Queensland, Australia
Perhaps that's an efficient use of extremely (scandalously) limited funds, in the long run.
Yeah, but the world is perhaps losing a hundred billion dollars annually. Every year of delay is another hundred billion lost. That's just money, not counting the patient loss.

Governments love talking about fiscal responsibility, but how responsible is it to lose billions and spend chump change on stopping that?
 

Gingergrrl

Senior Member
Messages
16,171
@PNWMom I agree with every word you said and would love to hear more of your story some time. I am also at the point where I feel I have enough evidence that if I can get IVIG or RTX approved, I will grab the opportunity as fast as I can.

Whether I have true ME/CFS or it's second cousin twice removed, no longer matters to me. I have proof of many autoimmune irregularities and want the opportunity to fix them, literally if it kills me, I want the opportunity. I will not end up on a ventilator.

If this is not what my life savings was for, then I don't know what it was! Excellent post and am so sorry about your daughter.
 

charles shepherd

Senior Member
Messages
2,239
I will shortly be off to London for two days involving parliamentary and research meetings - so will not be contributing to this discussion again till Thursday

And thanks to everyone who has passed on interesting information back channel - much appreciated
 
Last edited: